Epidemiologic Survey to Describe the Current Medical Practice of General Practitioners Treating Subjects With Type 2 Diabetes Mellitus in Latina

Diabetes Mellitus, Type 2 Clinical Trial

— DEAL  

Official title:

A Multi-center, Epidemiologic Survey to Describe the Current Medical Practice of General Practitioners Treating Subjects With Type 2 Diabetes Mellitus in Latin America

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01387165
• Other study ID #: 105407
• Status: Completed
• Phase: N/A
• First received: April 14, 2011
• Last updated: June 7, 2017
• Start date: October 2004
• Est. completion date: October 2005

Study information

• Verified date: May 2017
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The DEAL (Diabetes En America Latina) study was a multicenter, cross-sectional, epidemiological, questionnaire based study carried out between October 2004 and October 2005 in 9 Latin American countries.

Description:

The DEAL (Diabetes En America Latina) study was a multicenter, cross-sectional, epidemiological, questionnaire based study carried out between October 2004 and October 2005 in 9 Latin American countries. General practitioners (GP) from private settings were selected for participation in the study if they were in full time active clinical practice (three or more days per week and treating at least 100 patients per week), had been practicing for at least two years and were seeing at least five type 2 diabetes mellitus (T2DM) patients per week. Over a period of two weeks after receipt of study questionnaires, GPs were required to review the charts of the first 10 (+/- 2) consecutive diabetic patients to visit the clinic and to provide information about their treatment in accordance with the supplied questionnaire.

Patients were eligible for inclusion in the study if they were males or females aged 18-75 with Type II Diabetes Mellitus - T2DM - (defined by the criteria of the American Diabetes Association (12)), were receiving an oral hypoglycemic agent (OHA) or insulin and had given written informed consent, where required. Measurement of glycosylated hemoglobin (HbA1c) performed at the diagnosis and within the previous three months was collected; if the measure was not available for the period, the sponsor supported the laboratory test when necessary, according to the physician's judgment of the patient's need.

Demographic data were collected including information regarding the patient's lifestyle. The most recent fasting blood glucose, lipid level and blood pressure measurements were recorded along with the existence of diabetes related complications such as dyslipidemia, hypertension, macrovascular diseases, eye disorders, kidney disorders, erectile dysfunction and diabetic neuropathy. Antidiabetic medication and/or insulin therapy and therapy for prevention of macrovascular events were also recorded. Information was collected on visits to specialists, challenges to managing the patient's T2DM and on future plans for management. No explanations or clarifications related to the questions were provided and the physicians answered them based on their own understanding. Instructions on how to answer the questionnaire were provided to maximize the validation of the questionnaires.

Descriptive statistical analysis was performed on all variables. Multivariate logistic regression analyses were performed to test the possibility of association between the outcome measures and duration of disease. The independent variables were age, gender, BMI (body-mass index) category, current prescription, drug insurance coverage, glycemic management, lifestyle, number of co-morbidities and compliance to recommendations/therapy. All statistical analyses were conducted using SAS software. A p value <0.05 was considered statistically significant.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 3592
• Est. completion date: October 2005
• Est. primary completion date: October 2005
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Males and females 18-75 years of age, inclusive,

• Males and females with T2DM, as defined by the criteria of the American Diabetes Association (2003),

• Males and females under oral anti-diabetics (OAD) or insulin treatment for diabetes and

• Males and females that have given written informed consent.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2

Intervention

Drug:
• Treatment
were receiving an oral hypoglycemic agent (OHA) or insulin

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The achievement of the planned completed number of questionnaires.		up to 1 year
Secondary	Changes in glycemic parameters in accordance with the historical information provided by the GPs and her/his judgement of control based on that information.		up to 1 year
Secondary	Proportion of subjects who respond to any given treatment applied through the level of HbA1c responders (defined as subjects who have achieved HbA1c <7%)		up to 1 year
Secondary	Assessment of total cholesterol		up to 1 year
Secondary	Assessment of free fatty acids		up to 1 year
Secondary	Assessment of high-density lipoprotein		up to 1 year
Secondary	Assessment low-density lipoprotein		up to 1 year
Secondary	Assessment of triglycerides		up to 1 year
Secondary	Assessment of LDL relative flotation		up to 1 year
Secondary	Assessment of total cholesterol/HDL ratio		up to 1 year
Secondary	Assessment of LDL/HDL ratio		up to 1 year
Secondary	Assessment of fasting blood glucose		up to 1 year

External Links

•   Control of type 2 diabetes mellitus among general practitioners in private practice in nine countries of Latin America